Secondary analysis findings from the EMPACT-MI trial highlight empagliflozin's significant cardiovascular and kidney benefits when initiated soon after an acute myocardial infarction.

Finerenone may lower risks for kidney and cardiovascular events for adults with chronic kidney disease and type 2 diabetes, ...

The approval was supported by data from the randomized, double-blind, placebo-controlled, event-driven phase 3 FINEARTS-HF study.

Legionella pneumophila is a bacterium found in natural water sources and artificial water systems. The most widely reported manifestation of Legionella infection is pneumonia, which is also known as ...

Historically, managing type 2 diabetes in advanced chronic kidney disease (CKD) has been challenging due to a lack of therapies and increased risks for adverse events.

The FDA expanded the indication for finerenone (Kerendia) in heart failure (HF), drug manufacturer Bayer announced.

Declining oral function linked to lifestyle diseases like diabetes, high cholesterol, and kidney dysfunction in adults aged ...

Finerenone gained FDA approval for heart failure treatment, showcasing significant benefits in reducing cardiovascular events ...

Silent graft occlusion after coronary artery bypass grafting is detected before hospital discharge and is linked to ...

Learn about whether there is a risk of kidney cancer recurrence after a nephrectomy. This article also looks at ways to reduce the risk of recurrence.

Nursing care plans for CKD help monitor and manage disease progression by providing guidelines for identifying and resolving kidney-related issues. Learn more.

Berlin: Bayer has received approval from the U.S. Food and Drug Administration (FDA) for finerenone (Kerendia), a ...